211 related articles for article (PubMed ID: 25678082)
1. Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation.
Mahal K; Biersack B; Caysa H; Schobert R; Mueller T
Invest New Drugs; 2015 Jun; 33(3):541-54. PubMed ID: 25678082
[TBL] [Abstract][Full Text] [Related]
2. 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model.
Schobert R; Biersack B; Dietrich A; Effenberger K; Knauer S; Mueller T
J Med Chem; 2010 Sep; 53(18):6595-602. PubMed ID: 20731355
[TBL] [Abstract][Full Text] [Related]
3. Role of JNK and NF-κB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells.
Mahal K; Ahmad A; Sethi S; Resch M; Ficner R; Sarkar FH; Schobert R; Biersack B
Cell Oncol (Dordr); 2015 Dec; 38(6):463-78. PubMed ID: 26358135
[TBL] [Abstract][Full Text] [Related]
4. Gold(I) biscarbene complexes derived from vascular-disrupting combretastatin A-4 address different targets and show antimetastatic potential.
Muenzner JK; Biersack B; Kalie H; Andronache IC; Kaps L; Schuppan D; Sasse F; Schobert R
ChemMedChem; 2014 Jun; 9(6):1195-204. PubMed ID: 24648184
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of carbamates derived from aminocombretastatin A-4 as vascular disrupting agents.
Conesa-Milián L; Falomir E; Murga J; Carda M; Meyen E; Liekens S; Alberto Marco J
Eur J Med Chem; 2018 Mar; 147():183-193. PubMed ID: 29432949
[TBL] [Abstract][Full Text] [Related]
6. Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models.
Reipsch F; Biersack B; Lucas H; Schobert R; Mueller T
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884888
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410).
Cai YC; Zou Y; Ye YL; Sun HY; Su QG; Wang ZX; Zeng ZL; Xian LJ
Invest New Drugs; 2011 Apr; 29(2):300-11. PubMed ID: 20012336
[TBL] [Abstract][Full Text] [Related]
8. Biological evaluation of 4,5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents.
Mahal K; Schruefer S; Steinemann G; Rausch F; Schobert R; Biersack B; Höpfner M
Cancer Chemother Pharmacol; 2015 Apr; 75(4):691-700. PubMed ID: 25618416
[TBL] [Abstract][Full Text] [Related]
9. 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation.
Mahal K; Kahlen P; Biersack B; Schobert R
Exp Cell Res; 2015 Aug; 336(2):263-75. PubMed ID: 26101158
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic and antivascular 1-methyl-4-(3-fluoro-4-methoxyphenyl)-5-(halophenyl)-imidazoles.
Biersack B; Muthukumar Y; Schobert R; Sasse F
Bioorg Med Chem Lett; 2011 Nov; 21(21):6270-3. PubMed ID: 21963303
[TBL] [Abstract][Full Text] [Related]
11. Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells.
Galmarini CM; Martin M; Bouchet BP; Guillen-Navarro MJ; Martínez-Diez M; Martinez-Leal JF; Akhmanova A; Aviles P
BMC Cancer; 2018 Feb; 18(1):164. PubMed ID: 29415678
[TBL] [Abstract][Full Text] [Related]
12. The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1α Activation.
Porcù E; Persano L; Ronca R; Mitola S; Bortolozzi R; Romagnoli R; Oliva P; Basso G; Viola G
Sci Rep; 2016 Jun; 6():27886. PubMed ID: 27292568
[TBL] [Abstract][Full Text] [Related]
13. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.
Wang F; Yang Z; Liu Y; Ma L; Wu Y; He L; Shao M; Yu K; Wu W; Pu Y; Nie C; Chen L
Bioorg Med Chem; 2015 Jul; 23(13):3337-50. PubMed ID: 25937236
[TBL] [Abstract][Full Text] [Related]
15. Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects.
Jiang Z; Wu M; Miao J; Duan H; Zhang S; Chen M; Sun L; Wang Y; Zhang X; Zhu X; Zhang L
Int J Biochem Cell Biol; 2013 Aug; 45(8):1710-9. PubMed ID: 23702033
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
[TBL] [Abstract][Full Text] [Related]
17. Novel imidazole-based combretastatin A-4 analogues: evaluation of their in vitro antitumor activity and molecular modeling study of their binding to the colchicine site of tubulin.
Bellina F; Cauteruccio S; Monti S; Rossi R
Bioorg Med Chem Lett; 2006 Nov; 16(22):5757-62. PubMed ID: 16950621
[TBL] [Abstract][Full Text] [Related]
18. CA-1H, a novel oxazole bearing analogue of combretastatin A-4, disrupts the tumor vasculatures and inhibits the tumor growth via inhibiting tubulin polymerization.
Han F; Wang P; Zhang W; Li J; Zhang Q; Qi X; Liu M
Biomed Pharmacother; 2016 May; 80():151-161. PubMed ID: 27133052
[TBL] [Abstract][Full Text] [Related]
19. Combretastatin A-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors.
Mahal K; Biersack B; Schruefer S; Resch M; Ficner R; Schobert R; Mueller T
Eur J Med Chem; 2016 Aug; 118():9-20. PubMed ID: 27116710
[TBL] [Abstract][Full Text] [Related]
20. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton.
Hayot C; Farinelle S; De Decker R; Decaestecker C; Darro F; Kiss R; Van Damme M
Int J Oncol; 2002 Aug; 21(2):417-25. PubMed ID: 12118340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
